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Abstract
Introduction: Drug-drug interactions are an important clinical problem in pharmacotherapy. This study is focused on 
different types of drugs used in a psychiatric hospital.
Materials and methods: The pharmacoepidemiological study included the analysis of medical records of 500 psychi-
atric inpatients. The patients were divided into 2 groups: under 65 and over 65 years of age. All the drug prescriptions 
were analyzed to identify the combinations of drugs that can induce drug-drug interactions and determine their clinical 
significance.
Results and discussion: Over 77% of hospitalized patients were administered drug combinations that could induce 
drug-drug interactions, most of which were of moderate clinical significance. A reliable association was found between 
the patient’s age, the clinical significance of drug-drug interactions, and the pharmacotherapy structure. The most com-
mon irrational drug combinations were identified.
Conclusion: Timely analysis of drug prescriptions for potential drug-drug interactions can enhance the safety of phar-
macotherapy and decrease the risk of adverse drug reactions in the psychiatric inpatient setting.
Keywords
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Introduction
The current rational drug therapy of psychiatric diseases 
is based on the two main principles of efficacy and safe-
ty. The former aspect is quite successfully controlled by 
clinical practitioners on the basis of changes in the clini-
cal condition, whereas safety monitoring requires certain 
skills from the physician. A correct drug combination is 
one of the approaches to safe psychopharmacotherapy. 
Comorbidities, drug resistance, and willingness to accele-
rate recovery are the causes of multiple drug prescription, 
which increases the risk of adverse drug reactions, which 
in this case are mainly due to drug-drug interactions.
Drug-drug interactions lead to changes in the efficacy 
and safety of a medication administered concomitantly 
or sequentially with another medication. Investigators 
believe that the rather frequent development of adverse 
effects as a result of the aforementioned mechanism may 
be associated with some underestimation of the risk by 
clinical practitioners (Hahn et al. 2013, de Leon 2019) 
and depends on the number of co-administered medicati-
ons (Castilho et al. 2018). Development of adverse drug 
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reactions resulting from the use of an irrational drug com-
bination can lead to drug-induced issues associated with 
a worsening clinical condition of the patient, prolonged 
hospitalization, higher expenses for a healthcare instituti-
on, and, according to some authors, decreased life expec-
tancy (Oertle 2012, Murtaza et al. 2015).
It should be mentioned that irrational combinations do 
not necessarily involve drug-drug interactions; therefore 
this paper will touch upon potential interactions. According 
to B.Astrand, 17% to 23% of drug combinations are asso-
ciated with such a risk, and only from 6% to 8% of them 
actually result in an interaction (Astrand 2009). However, 
a number of factors, such as a narrow therapeutic index of 
many psychoactive drugs (Spina et al. 2016, Hiemke et al. 
2018), predominantly hepatic metabolism involving the cy-
tochrome P450 system (Guo et al. 2012, de Leon and Spina 
2018), and antipsychotic polytherapy (use of several anti-
psychotic drugs) (Tranulis et al. 2008, Correll et al. 2009, 
Misawa et al. 2011), can increase the occurrence of drug-
drug interactions in the treatment of psychiatric inpatients.
In view of the existing risk of decreased safety of drug 
therapy, timely identification of irrational combinations 
and prediction of drug-drug interactions appears to be the 
optimal approach. Foreign researchers believe that con-
sideration of potential drug-drug interactions allows to 
avoid up to 72% of adverse drug reactions (Pirmohamed 
et al. 2004) and that their timely identification is an essen-
tial treatment safety factor (Andersson et al. 2013).
Objective of the Study: To conduct a frequency ana-
lysis of potential drug-drug interactions in the psychiatric 
hospital.
Materials and methods
This was a pharmacoepidemiological study that included 
an analysis of medical records of patients hospitalized in 
a psychiatric medical institution, undertaken to identify 
combinations of drugs that could be involved in an inter-
action. This analysis was aided by a drug-drug interaction 
identification tool, the Drug Interaction Checker found 
at http://www.drugs.com, which provides data that is in 
agreement with the official prescribing information for 
medicinal products approved by the United States Food 
and Drug Administration (FDA).The information obtain-
ed on potential drug-drug interactions was compared with 
the official instructions for medical use from the State 
Register of Medicines. The Drug Interaction Checker di-
vides potential interactions into major (highly clinically 
significant, potentially hazardous), moderate (moderately 
clinically significant), and minor (least clinically signifi-
cant) ones, based on clinical significance grade.
The inclusion criteria for the study were the presence 
in the patient’s prescription list of a medications of the 
Psycholeptics or Psychoanaleptics subgroup (Anatomical 
Therapeutic Chemical Classification System codes N05 
and N06) and polypharmacy (concomitant use of 5 or 
more medications).
Statistical processing of the data was performed by 
means of descriptive statistics, as well as the non-parame-
tric Pearson’s chi-squared test, using the AnalystSoft Inc., 
StatPlus:mac, Version 6.8.1.0 software.
Results and discussion
The study enrolled 500 patients receiving psychiatric care 
in inpatient settings. Since elderly patients are at higher 
risk of serious adverse drug reactions as a result of po-
lypharmacy and physiological specifics, the sample was 
divided into 2 equal groups: patients under 65 and over 65 
years of age. This division is used by most foreign tools 
designed to counteract irrational drug prescription in el-
derly patients. The mean age of the study subjects was 
62.23 ± 16.11 years; in patients under 65, it was 49.32 ± 
11.76 years, and in patients aged over 65, the mean age 
was 75.14 ± 6.88 years. Of the younger subjects, 106 
(42.40%) were males and 144 (57.60%) were females. 
In the elderly patients’ group, 72 (28.80%) were males 
and 178 (71.20%) were females. Overall, there were 178 
(35.60%) male and 322 (64.40%) female subjects.
The mean number of administered drugs was 7.67 ± 
2.11; in patients under 65 it was 7.27 ± 1.83, and patients 
aged over 65 received 8.07 ± 2.30 drugs concomitantly. 
Assessment of co-administration percentages revealed 
that most subjects (21%) concomitantly received 6 me-
dications, while 17.2%, 16.4%, 14.8%, and 11% of the 
patients were co-administered 8, 7, 5, and 9 drugs, res-
pectively. The proportions of patients with other numbers 
of co-administered drugs were less than 10%. It should 
be emphasized that all the medications recorded in the 
prescription lists were registered under their international 
nonproprietary names for the purpose of this study, with 
active ingredients in combination drugs considered sepa-
rately. The pharmacological characteristics of drugs pres-
cribed to the study subjects are categorized in accordance 
with the international Anatomical Therapeutic Chemical 
(ATC) Classification System (Table 1).
The nosological analysis of the sample revealed that 
155 (31%) and 152 (30.4%) patients were diagnosed with 
“Other mental disorders due to brain damage and dys-
function and to physical disease” and “Schizophrenia”, 
respectively. “Dementia in other diseases classified else-
where” was diagnosed in 65 patients (13.6%), “Vascular 
dementia” – in 36 (7.2%), “Personality and behavioural 
disorders due to brain disease, damage and dysfunction” – 
in 14 (2.8%), “Schizoaffective disorders” – in 11 (2.2%), 
“Other anxiety disorders” – in 11 (2.2%), “Dementia in 
Alzheimer’s disease” – in 10 (2%), “Moderate mental 
retardation” – in 9 (1.8%), and “Specific personality di-
sorders” – in 6 (1.2%) patients. Diagnoses that had a fre-
quency of less than 1% are not mentioned.
The analysis of the prescription rates of drug combina-
tions which can lead to drug-drug interactions in the psy-
chiatric inpatient setting demonstrated that 386 (77.2%) 
subjects were at risk; such combinations were taken by 
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Table 1. Pharmacological characteristics of prescribed drugs in accordance with the ATC classification system
ATC code Number of drugs Percentage (%)
N05 Psycholeptics 19 12.58%
N06 Psychoanaleptics 18 11.92%
J01 Antibacterials for systemic use 17 11.26%
A11 Vitamins 6 3.97%
A02 Drugs for acid related disorders 5 3.31%
A10 Drugs used in diabetes 5 3.31%
B03 Antianemic preparations 5 3.31%
B05 Blood substitutes and perfusion solutions 5 3.31%
C01 Cardiac therapy 5 3.31%
C07 Beta blocking agents 5 3.31%
N04 Anti-parkinson drugs 5 3.31%
R06 Antihistamines for systemic use 5 3.31%
C03 Diuretics 4 2.65%
C09 Agents acting on the renin-angiotensin system 4 2.65%
N07 Other nervous system drugs 4 2.65%
B01 Antithrombotic agents 3 1.99%
C08 Calcium channel blockers 3 1.99%
C10 Lipid modifying agents 3 1.99%
J05 Antivirals for systemic use 3 1.99%
N03 Antiepileptics 3 1.99%
A03 Drugs for functional gastrointestinal disorders 2 1.32%
A12 Mineral supplements 2 1.32%
C05 Vasoprotectives 2 1.32%
J04 Antimycobacterials 2 1.32%
M01 Anti-inflammatory and antirheumatic products 2 1.32%
A05 Bile and liver therapy 1 0.66%
A07 Antidiarrheals, intestinal anti-inflammatory/anti-infective agents 1 0.66%
A09 Digestives, including enzymes 1 0.66%
A13 Tonics 1 0.66%
B06 Other hematological agents 1 0.66%
C04 Peripheral vasodilators 1 0.66%
G04 Urologicals 1 0.66%
H02 Corticosteroids for systemic use 1 0.66%
M03 Muscle relaxants 1 0.66%
N02 Analgesics 1 0.66%
R05 Cough and cold preparations 1 0.66%
R07 Other respiratory system products 1 0.66%
S01 Ophthalmologicals 1 0.66%
V03 All other therapeutic products 1 0.66%
199 (79.6%) elderly patients and 187 (74.8%) subjects 
under 65 years of age, which was not statistically signifi-
cant, apparently due to the fact that polypharmacy was an 
inclusion criterion in this study and because the patients 
under 65 years of age also received 5 or more medications 
at baseline. Out of 500 patients, 114 (22.8%) had no risk 
of drug-drug interaction.
There were 1352 cases of drug combinations potenti-
ally leading to a drug-drug interaction in the study sam-
ple in total; 652 (48.22%) of these cases were registered 
in patients under 65 years of age and 700 (51.78%) – in 
subjects aged over 65 years. The number of unique drug 
pairs was 373.
The analysis of the frequency of occurrence of irratio-
nal drug combinations by their clinical significance grade 
is of particular practical interest for predicting the risk of 
adverse drug reactions resulting from drug-drug interac-
tions. The results of the analysis are presented in Table 2.
As Table 2 shows, highly significant drug interac-
tions (potentially hazardous, major) were observed in 
6.14% of the elderly patients and 17.02% of the subjects 
under 65 years of age, whereas interactions of modera-
te clinical significance accounted for most of the cases 
(78.77%). With regard to patients with different clinical 
significance grades of drug-drug interactions, potential 
major interactions prevailed in patients under 65 years of 
age (odds ratio [OR] = 3.512, 95% confidence interval 
[CI] 2.251–5.479); while moderate (OR = 1.496, 95% 
CI 1.007–2.221) and minor (OR = 4.125, 95% CI 2.412–
7.054) interactions prevailed in patients over 65 years of 
age (statistically significant difference).
On the basis of the obtained results, the goal of the 
present study was to determine the possible causes of this 
distribution. To do this, all the potential drug interactions 
were divided into 3 groups based on the pharmacological 
class of the medication and a type of the hospital: inter-
actions between neurotropic drugs, interactions between 
neurotropic drugs and somatic drugs, and interactions 
between somatic drugs. According to the ATC Classifica-
tion System developed by the WHO, in this study all the 
medications affecting the nervous system (code N) were 
classified as neurotropic drugs and all other drugs as “so-
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matic” drugs. This division was used to establish the role 
of principal drugs for the treatment of psychiatric diseases 
in the development of drug interactions, their clinical sig-
nificance and association with the patient’s age. The main 
results of this analysis are presented in Table 3.
The detected predominance of potential major (OR = 
2.407, 95% CI 1.093–5.303) and moderate (OR = 4.877, 
95% CI 3.735–6.368) drug-drug interactions between 
neurotropic medications in patients under 65 years of age 
was due to antipsychotic polypharmacy, attempts to over-
come drug resistance, and, possibl,y practitioners’ focus 
on the efficacy of the drug therapy rather than its safety 
due to the age of patients in this group. The predominance 
of potential major (OR = 6.688, 95% CI 2.131–20.991) 
and moderate (OR = 5.444, 95% CI 3.965–7.477) drug-
drug interactions between somatic drugs in patients above 
65 years of age was apparently due to comorbidities of the 
elderly and, as a result, to the changes in the pharmacolo-
gical structure of drugs involved in interactions.
It should be mentioned that the Drug Interaction Chec-
ker tool, which was used to detect potential drug interacti-
ons, prescribes certain courses of action for clinical prac-
titioners and grades interactions in the following manner: 
“Contraindicated”, “Generally avoid”, “Monitor closely”, 
“Adjust dose” for major interactions; “Generally avoid”, 
“Monitor”, “Adjust dose”, “Adjust dosing interval” for 
moderate interactions. An assessment of the frequency 
of potential drug interactions depending on the case ma-
nagement strategy is presented in Table 4. Minor interac-
tions do not require strategy-based grading.
The identification of certain potentially interacting drug 
pairs is of particular importance and significance, because 
Table 4. Pharmacoepidemiological characteristics of potential drug-drug interactions according to management strategy
Potential drug-drug interactions by 
management strategy
Patients under 65 years of age: 
n (%)
Patients over 65 years of age: 
n (%)
Total number of patients: 
n (%)
Types of major interactions and frequency
Contraindicated 32 (28.83%) 11 (25.58%) 43 (27.92%)
Generally avoid 1 (0.90%) 0 (0.00%) 1 (0.65%)
Monitor closely 78 (70.27%) 32 (74.42%) 110 (71.43%)
Adjust dose 0 (0.00%) 0 (0.00%) 0 (0.00%)
Types of moderate interactions and frequency
Generally avoid 1 (0.20%) 7 (1.24%) 8 (0.75%)
Monitor 498 (99.20%) 541 (96.09%) 1039 (97.56%)
Adjust dose 0 (0.00%) 1 (0.18%) 1 (0.09%)
Adjust dosing interval 3 (0.60%) 14 (2.49%) 17 (1.60%)
Table 2. Pharmacoepidemiological characteristics of potential drug-drug interactions by clinical significance grade
Potential drug-drug interactions by 
clinical significance grade
Patients under 65 years of age: 
n (%)
Patients over 65 years of age: 
n (%)
Total number of patients: 
n (%)
Number of major interactions 111 (17.02%) 43 (6.14%) 154 (11.39%)
Number of moderate interactions 502 (76.99%) 563 (80.43%) 1065 (78.77%)
Number of minor interactions 39 (5.98%) 94 (13.43%) 133 (9.84%)
Number of patients (major interactions) 89* (35.60%) 34 (13.60%) 123 (24.60%)
Number of patients (moderate interactions) 171* (68.40%) 191 (76.40%) 362 (72.40%)
Number of patients (minor interactions) 20* (8.00%) 66 (26.40%) 86 (17.20%)
Notes: * – p<0.05, statistically significant differences between study groups.
Table 3. Occurrence of drug-drug interactions based on drug prescription structure
Drug-drug interactions based on drug prescription 
structure
Major (under 65 years of age) Major (over 65 years of age)
Neurotropic + Neurotropic 91* (81.2%) 27 (64.2%)
Neurotropic + Somatic 16 (14.2%) 5 (11.9%)
Somatic + Somatic 5* (4.4%) 10 (23.8%)
Drug-drug interactions based on drug prescription 
structure
Moderate
(under 65 years of age)
Moderate 
(over 65 years of age)
Neurotropic + Neurotropic 290* (57.8%) 124 (21.9%)
Neurotropic + Somatic 151 (30.1%) 200 (35.4%) 
Somatic + Somatic 60* (11.9%) 240 (42.5%)
Drug-drug interactions based on drug prescription 
structure
Minor 
(under 65 years of age)
Minor 
(over 65 years of age) 
Neurotropic + Neurotropic 1 (2.5%) 0 (0%)
Neurotropic + Somatic 10* (25.6%) 10 (10.6%)
Somatic + Somatic 28* (71.7%) 84 (89.3%)
Notes: * – p<0.05, statistically significant differences between study groups.
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Table 5. Pharmacoepidemiological Characteristics of Irrational Drug Combinations and Their Occurrence
Interacting drug pairs Number Percentage Clinical significance grade
haloperidol + trihexyphenidyl 72 5.33% Moderate
acetylsalicylic acid + enalapril 49 3.62% Moderate
clozapine + trihexyphenidyl 43 3.18% Moderate
chlorpromazine + trihexyphenidyl 38 2.81% Moderate
enalapril + thioridazine 34 2.51% Moderate
clozapine + haloperidol 30 2.22% Major
acetylsalicylic acid + metoprolol 29 2.14% Minor
chlorpromazine + haloperidol 27 2.00% Major
acetylsalicylic acid + bisoprolol 21 1.55% Minor
trifluoperazine + trihexyphenidyl 21 1.55% Moderate
amitriptyline + trihexyphenidyl 19 1.41% Moderate
acetylsalicylic acid + lisinopril 19 1.41% Moderate
carbamazepine + chlorpromazine 19 1.41% Moderate
enalapril + risperidone 15 1.11% Moderate
risperidone + trihexyphenidyl 15 1.11% Moderate
this may help draw the practitioner’s attention to the most 
clinically relevant combinations. The frequency rates of 
these combinations detected during the pharmacoepide-
miological analysis of drug therapy in psychiatric inpatient 
settings are presented in Table 5. Combinations with oc-
currence rates of less than 1% are excluded from the table.
The aforementioned most common drug combinations 
warrant some comment. The most common potential drug-
drug interaction, that between haloperidol and trihexyp-
henidyl, is moderate and, based on the information included 
in the Drug Interaction Checker database, can result in CNS 
inhibition, development of tardive dyskinesia, and enhan-
ced anticholinergic effects on the body. Evidently, in most 
cases this combination is used to treat extrapyramidal disor-
ders developing during neuroleptic therapy; however, the 
practitioner should remember about the possible adverse ef-
fects of this therapy and avoid prescribing antiparkinsonian 
drugs for prophylactic purposes, which is also confirmed 
in the clinical guidelines for the diagnosis and treatment of 
schizophrenia. The same type of interaction was registered 
for the third and fourth most common drug combinations, 
clozapine plus trihexyphenidyl and chlorpromazine plus 
trihexyphenidyl, as well as for the combinations of trifluo-
perazine plus trihexyphenidyl, amitriptyline plus trihexyp-
henidyl, and risperidone plus trihexyphenidyl.
The second most common potential drug interaction, 
that between acetylsalicylic acid and enalapril, and the 
combination of acetylsalicylic acid plus lisinopril, which 
was among the top fifteen combinations, have the same 
mechanism of action and require the same management 
strategy. This interaction may result in diminished effects 
of ACE inhibitors due to blocked prostaglandin synthesis. 
To a lesser extent, this applies to low doses of acetylsali-
cylic acid, which was observed in the present study. Ho-
wever, the potential of acetylsalicylic acid to increase the 
incidence of decompensated conditions should be borne 
in mind (Ponikowski et al. 2016).
The fifth most common combination, enalapril plus 
thioridazine, as well as the combination of enalapril and 
risperidone, is classified as moderate and associated with 
a possible increase in the hypotensive effect of the ACE 
inhibitor during antipsychotic therapy and with a risk of 
orthostatic hypotension.
The combinations of clozapine plus haloperidol and 
chlorpromazine plus haloperidol are the only ones classi-
fied according to the potential drug interaction identifica-
tion tool (Drug Interaction Checker) as major and dange-
rous, and observed in more than 1% of all the cases. The 
former combination is associated with a risk of orthostatic 
hypotension, collapse, respiratory depression, and enhan-
ced anticholinergic effects. The latter combination may be 
associated with prolongation of the QT interval on the elec-
trocardiogram and a risk of “torsade de pointes”. It should 
be emphasized that the service used in the study permits 
use of this treatment and allows, in some cases, adminis-
tration of antipsychotic combination therapy; however, it 
prescribes “Monitor closely” as a management strategy.
Combinations of acetylsalicylic acid and beta-blockers 
have the lowest clinical significance, particularly with the 
anti-platelet agent’s doses recommended for use. The pair 
of carbamazepine and chlorpromazine requires monito-
ring of the general depressant effects on the central ner-
vous and respiratory systems.
Conclusion
The reported analysis of frequency of potential drug 
interactions in the psychiatric hospital yielded the fol-
lowing findings. Over 77% of the hospitalized patients 
were administered drug combinations that could induce 
drug-drug interactions, most of which were classified as 
potential interactions of moderate clinical significance. 
Comparing age-related specifics, it was found that major 
potential drug interactions, particularly between neurot-
ropic agents, prevailed in patients under 65 years of age, 
whereas moderate and minor interactions, particularly be-
tween somatic drugs, were predominant in patients aged 
over 65 years. A timely analysis of drug prescriptions for 
potential drug-drug interactions can enhance the safety of 
pharmacotherapy and decrease the risk of adverse drug 
reactions in the psychiatric inpatient setting.
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